CND319 / UCB - LARVOL DELTA

A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases (clinicaltrials.gov) - P1 | N=105 | Not yet recruiting | Sponsor: Candid Therapeutics

First-in-human • New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Sjogren's Syndrome

A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases (clinicaltrials.gov) - P1 | N=105 | Recruiting | Sponsor: Candid Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Sjogren's Syndrome